GT200000161A - Compuestos para el tratamiento de la isquemia. - Google Patents
Compuestos para el tratamiento de la isquemia.Info
- Publication number
- GT200000161A GT200000161A GT200000161A GT200000161A GT200000161A GT 200000161 A GT200000161 A GT 200000161A GT 200000161 A GT200000161 A GT 200000161A GT 200000161 A GT200000161 A GT 200000161A GT 200000161 A GT200000161 A GT 200000161A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- agonists
- profarmacos
- discussion
- ischemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
ESTA INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA ADJUNTA, PROFARMACOS DE LOS MISMOS Y SALES FARMACEUTICAMENTE ACEPTABLES DE DICHOS COMPUESTOS Y DE DICHOS PROFARMACOS, EN LA QUE X = OXI, METILENO O TIO; Y = CH O N; Z = ES H, ALQUILO, TRIFLUOROMETILO O HALO; LAS DEMAS LETRAS REPRESENTAN UNA GRAN VARIEDAD DE SUSTITUYENTES QUE INDIVIDUAL O CONJUNTAMENTE FORMAN PARTE DE LAS CARACTERISTICAS DE ESTE INGREDIENTE ACTIVO Y DEBERAN COTEJARSE EN EL DOCUMENTO ORIGINAL, LOS COMPUESTOS SON AGONISTAS DE A3 UTILES PARA LA REDUCCION DE LESIONES DE TEJIDOS PRODUCIDAS POR ISQUEMIA O HIPOXIA DE LOS TEJIDOS. EL INVENTO REIVINDICA ADEMAS DEL PROCEDIMIENTO DE SINTESIS DE LOS DIFERENTES COMPUESTOS, LOS PROCEDIMIENTOS PARA USAR TALES AGONISTAS, Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES AGONISTAS DE A3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15682899P | 1999-09-30 | 1999-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000161A true GT200000161A (es) | 2002-03-22 |
Family
ID=22561263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000161A GT200000161A (es) | 1999-09-30 | 2000-09-28 | Compuestos para el tratamiento de la isquemia. |
Country Status (41)
| Country | Link |
|---|---|
| EP (1) | EP1216257B1 (es) |
| JP (1) | JP2003510331A (es) |
| KR (1) | KR100481605B1 (es) |
| CN (1) | CN1374967A (es) |
| AP (1) | AP2002002458A0 (es) |
| AR (1) | AR029887A1 (es) |
| AT (1) | ATE312117T1 (es) |
| AU (1) | AU778185B2 (es) |
| BG (1) | BG106636A (es) |
| BR (1) | BR0014384A (es) |
| CA (1) | CA2386079A1 (es) |
| CO (1) | CO5180581A1 (es) |
| CR (1) | CR6592A (es) |
| CZ (1) | CZ20021020A3 (es) |
| DE (1) | DE60024649D1 (es) |
| EA (1) | EA005422B1 (es) |
| EC (1) | ECSP003682A (es) |
| EE (1) | EE200200172A (es) |
| GE (1) | GEP20043241B (es) |
| GT (1) | GT200000161A (es) |
| HK (1) | HK1049011A1 (es) |
| HR (1) | HRP20020253A2 (es) |
| HU (1) | HUP0202807A3 (es) |
| IL (1) | IL148222A0 (es) |
| IS (1) | IS6286A (es) |
| MA (1) | MA26822A1 (es) |
| MX (1) | MXPA02003308A (es) |
| MY (1) | MY133996A (es) |
| NO (1) | NO20021474L (es) |
| NZ (1) | NZ517177A (es) |
| OA (1) | OA12021A (es) |
| PA (1) | PA8503301A1 (es) |
| PE (1) | PE20010696A1 (es) |
| PL (1) | PL357371A1 (es) |
| SK (1) | SK4182002A3 (es) |
| TN (1) | TNSN00191A1 (es) |
| TR (1) | TR200200843T2 (es) |
| UA (1) | UA73525C2 (es) |
| WO (1) | WO2001023399A1 (es) |
| YU (1) | YU23102A (es) |
| ZA (1) | ZA200202461B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
| EP1241176A1 (en) * | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| WO2003039528A1 (en) * | 2001-11-02 | 2003-05-15 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| WO2003088978A1 (en) | 2002-04-18 | 2003-10-30 | Cv Therapeutics, Inc. | Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| JP2007513082A (ja) * | 2003-11-10 | 2007-05-24 | シエーリング アクチエンゲゼルシャフト | Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物 |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| CN101132802A (zh) | 2004-03-24 | 2008-02-27 | 法斯根有限责任公司 | 通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法 |
| EA011097B1 (ru) | 2004-05-07 | 2008-12-30 | Янссен Фармацевтика Н.В. | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| ES2432113T3 (es) * | 2004-07-28 | 2013-11-29 | Can-Fite Biopharma Ltd. | Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren |
| CA2576255A1 (en) * | 2004-08-09 | 2006-02-16 | Universite Catholique De Louvain | Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases |
| DE602005017159D1 (de) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | Oxysteroid-dehydrogenase-inhibitoren |
| DE602005018509D1 (de) * | 2004-08-30 | 2010-02-04 | Janssen Pharmaceutica Nv | N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer |
| ES2334246T3 (es) | 2004-08-30 | 2010-03-08 | Janssen Pharmaceutica Nv | Derivados triciclos de adamantilamida como inhibidores de la 11-beta-hidroxiesteroide-deshidrogenasa. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7910708B2 (en) | 2005-10-21 | 2011-03-22 | Novartis Ag | Anti-IL13 human antibodies |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| MX2009003185A (es) | 2006-09-29 | 2009-04-03 | Novartis Ag | Pirazolopirimidinas como inhibidores de lipido cinasa pi3k. |
| CA2667962A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| ES2442930T3 (es) | 2008-01-11 | 2014-02-14 | Novartis Ag | Pirimidinas como inhibidores de cinasas |
| PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
| US9199102B2 (en) | 2009-07-21 | 2015-12-01 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EP2464649A1 (en) | 2009-08-12 | 2012-06-20 | Novartis AG | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
| KR20120089463A (ko) | 2009-08-20 | 2012-08-10 | 노파르티스 아게 | 헤테로시클릭 옥심 화합물 |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| MX2013009767A (es) | 2011-02-25 | 2013-10-01 | Irm Llc | Compuestos y composiciones como inhibidores de trk. |
| JP5957526B2 (ja) | 2011-09-15 | 2016-07-27 | ノバルティス アーゲー | チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン |
| US20130209543A1 (en) | 2011-11-23 | 2013-08-15 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
| EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
| CN109512805B (zh) | 2012-05-08 | 2021-12-31 | 埃罗米克斯公司 | 用于治疗水通道蛋白介导的疾病的化合物 |
| RU2559776C2 (ru) * | 2012-08-20 | 2015-08-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления |
| CA2906542A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| CN112402434A (zh) | 2013-11-06 | 2021-02-26 | 埃罗米克斯公司 | 新配方 |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| RU2611339C2 (ru) * | 2014-02-17 | 2017-02-21 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| BR112017001695A2 (pt) | 2014-07-31 | 2017-11-21 | Novartis Ag | terapia de combinação |
| RU2582961C1 (ru) * | 2015-03-04 | 2016-04-27 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления |
| RU2712150C1 (ru) * | 2019-08-22 | 2020-01-24 | Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" | ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK62692D0 (es) * | 1992-05-14 | 1992-05-14 | Novo Nordisk As | |
| TW336938B (en) * | 1992-05-21 | 1998-07-21 | Pfizer | Calcium channel blocking polypeptides from filistata hibernalis |
| AU7331094A (en) * | 1993-07-13 | 1995-02-13 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | A3 adenosine receptor agonists |
-
2000
- 2000-09-05 CO CO00066880A patent/CO5180581A1/es not_active Application Discontinuation
- 2000-09-22 AU AU70352/00A patent/AU778185B2/en not_active Ceased
- 2000-09-22 BR BR0014384-7A patent/BR0014384A/pt not_active IP Right Cessation
- 2000-09-22 NZ NZ517177A patent/NZ517177A/en unknown
- 2000-09-22 JP JP2001526549A patent/JP2003510331A/ja active Pending
- 2000-09-22 TR TR2002/00843T patent/TR200200843T2/xx unknown
- 2000-09-22 AT AT00958949T patent/ATE312117T1/de not_active IP Right Cessation
- 2000-09-22 PL PL00357371A patent/PL357371A1/xx not_active Application Discontinuation
- 2000-09-22 CN CN00813154A patent/CN1374967A/zh active Pending
- 2000-09-22 WO PCT/IB2000/001353 patent/WO2001023399A1/en active IP Right Grant
- 2000-09-22 AP APAP/P/2002/002458A patent/AP2002002458A0/en unknown
- 2000-09-22 CZ CZ20021020A patent/CZ20021020A3/cs unknown
- 2000-09-22 OA OA1200200072A patent/OA12021A/en unknown
- 2000-09-22 MX MXPA02003308A patent/MXPA02003308A/es unknown
- 2000-09-22 EA EA200200316A patent/EA005422B1/ru not_active IP Right Cessation
- 2000-09-22 UA UA2002032515A patent/UA73525C2/uk unknown
- 2000-09-22 CA CA002386079A patent/CA2386079A1/en not_active Abandoned
- 2000-09-22 EE EEP200200172A patent/EE200200172A/xx unknown
- 2000-09-22 KR KR10-2002-7004177A patent/KR100481605B1/ko not_active IP Right Cessation
- 2000-09-22 YU YU23102A patent/YU23102A/sh unknown
- 2000-09-22 HU HU0202807A patent/HUP0202807A3/hu unknown
- 2000-09-22 GE GEAP20006392A patent/GEP20043241B/en unknown
- 2000-09-22 EP EP00958949A patent/EP1216257B1/en not_active Expired - Lifetime
- 2000-09-22 SK SK418-2002A patent/SK4182002A3/sk unknown
- 2000-09-22 DE DE60024649T patent/DE60024649D1/de not_active Expired - Lifetime
- 2000-09-25 PA PA20008503301A patent/PA8503301A1/es unknown
- 2000-09-27 PE PE2000001021A patent/PE20010696A1/es not_active Application Discontinuation
- 2000-09-28 AR ARP000105125A patent/AR029887A1/es unknown
- 2000-09-28 GT GT200000161A patent/GT200000161A/es unknown
- 2000-09-28 MY MYPI20004553 patent/MY133996A/en unknown
- 2000-09-28 EC EC2000003682A patent/ECSP003682A/es unknown
- 2000-09-29 IL IL14822200A patent/IL148222A0/xx unknown
- 2000-09-29 TN TNTNSN00191A patent/TNSN00191A1/fr unknown
-
2002
- 2002-02-18 CR CR6592A patent/CR6592A/es not_active Application Discontinuation
- 2002-02-26 IS IS6286A patent/IS6286A/is unknown
- 2002-03-15 MA MA26557A patent/MA26822A1/fr unknown
- 2002-03-25 NO NO20021474A patent/NO20021474L/no unknown
- 2002-03-26 HR HR20020253A patent/HRP20020253A2/xx not_active Application Discontinuation
- 2002-03-27 ZA ZA200202461A patent/ZA200202461B/xx unknown
- 2002-04-23 BG BG106636A patent/BG106636A/bg unknown
-
2003
- 2003-02-18 HK HK03101216.3A patent/HK1049011A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200000161A (es) | Compuestos para el tratamiento de la isquemia. | |
| AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| PA8442001A1 (es) | Derivados de pirimidina biciclica condensada | |
| GT200000005A (es) | Derivados biciclicos sustituidos utiles como agentes contra el cancer. | |
| CO4810375A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
| AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| AR048039A1 (es) | Profarmacos de piperazina y agentes antivirales de piperidina sustituidos | |
| PA8489501A1 (es) | Antibioticos cetolidos | |
| PA8507601A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| UY27350A1 (es) | Azaindoles | |
| PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
| PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| CR7069A (es) | Derivados de pirazol para el tratamiento de vih | |
| SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
| ECSP066643A (es) | PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2 | |
| PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
| AR040925A1 (es) | Compuestos de pirazol utiles como inhibidores de proteinquinasa | |
| CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| PA8559501A1 (es) | Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno | |
| PA8451801A1 (es) | Derivados de la 9-oxima eritromicina |